AstraZeneca (AZN)
Add to Watchlists Create an AlertAZN Key Stats
| Income Statement | |
| Revenue TTM | 27.01B |
| Revenue Quarterly YoY Growth | -13.12% |
| EPS Diluted TTM | 4.508 |
| EPS Diluted Quarterly YoY Growth | -36.22% |
| Net Income TTM | 5.668B |
| Profitability | |
| Gross Profit Margin Quarterly | 80.17% |
| Profit Margin Quarterly | 15.83% |
| Dividend | |
| Dividend Yield | 7.28% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 65.21B |
| Enterprise Value | 67.59B |
| PE Ratio TTM | 11.57 |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 2.925 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.458 |
| Free Cash Flow | 1.784B |
| Return on Equity | 25.39% |
AZN News
- Actavis says court blocks generic Pulmicort May 24
- Billionaire Jim Simons' Top Dividend Stock Holdings May 24
- Impax Launches Generic Zomig - Analyst Blog Zacks May 23
- Data on AstraZeneca's Naloxegol - Analyst Blog Zacks May 23
- Impax Launches Generic Zomig May 23
- Data on AstraZeneca's Naloxegol May 23
- 3 Stocks Dragging In The Drugs Industry May 23
- [$$] Digest Data on Nektar-AstraZeneca's Naloxegol May 22
- The 5 Highest-Paying Dividend Stocks in Big Pharma Fool May 22
- Do Major Drug Manufacturers Have Room to Grow? May 22
AZN Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AstraZeneca is up 34.49% over the last year vs S&P 500 Total Return up 27.77%, Sanofi up 64.11%, and GlaxoSmithKline up 25.97%.
AZN Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these AZN related companies
Pro Ratings for AZN
Pro Report PDF for AZN
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download AZN Pro Report PDF
Pro Strategies Featuring AZN
Did AstraZeneca make it into our Pro Portfolio Strategies?
AZN Profile
Sector: Healthcare
Industry: Drug Manufacturers - Major
AstraZeneca plc is a global pharmaceutical and biologics company headquartered in London, United Kingdom. It is the world's seventh-largest pharmaceutical company measured by revenues and has operations in over 100 countries. It has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. AstraZeneca PLC markets its products primarily to primary care and specialist doctors, and other healthcare professionals through distributors or local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992.
Other AZN Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AZN | 52.17 | +0.09 | +0.17% | 65.21B |
